Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe active lupus, a retrospective study shows.

The Lupus Foundation of America describes lupus as a chronic disease that attacks the immune system, the part of the body ...

Kris Aquino revealed her "pain and struggle" amid suffering from lupus flare fever for over two weeks now, appealing to the ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

A risk prediction score that uses machine learning and a patient’s genetic information may identify autoimmune conditions up ...

Researchers identified 4 prepregnancy conditions that were associated with better pregnancy outcomes among patients with SLE.

Lupus Alert Day serves a vital purpose. It encourages others to learn more about lupus, share information on social media, ...

In a new study, researchers explored experiences, perceptions, and health effects of a newly developed healthy lifestyle ...

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity and remission, and more time spent in those states, vs. standard therapy ...

The US National Institutes of Health defined Mixed Connective Tissue Disease as “a rare autoimmune disorder characterized by ...

AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) microarray. The MosaiQ ...